Related by context. Frequent words. (Click for all words.) 73 GSK # 62 AEG# 62 Initiates Phase II 62 novel orally administered 62 Inc. Nasdaq IMGN 61 non nucleoside polymerase 61 vascular disrupting agent 61 Voreloxin 60 Panzem R 60 CCX# 60 Initiate Phase 60 Aurora kinase 60 liposomal formulation 59 MEK inhibitor 59 www.syntapharma.com 59 PEG SN# 59 proteasome inhibitor 59 Presents Positive 59 KRN# 59 Pivotal Phase 58 poly ADP ribose polymerase 58 Belimumab 58 selective inhibition 58 Preclinical Data 58 Bortezomib 58 J Biol Chem 58 polymerase inhibitor 58 multi kinase inhibitor 58 RNAi Therapeutics 58 Drug Candidate 58 PSN# [002] 58 JAK1 58 HCV protease inhibitor 58 R sorafenib tablets 58 II Clinical Trial 58 AACR NCI EORTC 58 TELINTRA 58 FGFR 57 OXi# 57 www.pozen.com 57 please visit http:/www.supergen.com 57 Receives Orphan Drug Designation 57 Phase III Clinical Trial 57 smooth muscle contractility 57 developing Zerenex TM 57 Molecular Cancer 57 TLR9 agonist 57 orally bioavailable 57 HCV protease 57 www.delcath.com 57 ALN TTR 57 CORT # 57 Factor VIIa 57 CYC# 56 elotuzumab 56 epothilone 56 nitric oxide donating 56 anti mitotic 56 GLPG# 56 Clinical Trial Results 56 Phase Ib II 56 histone deacetylase 56 IMC #B 56 Nexavar ® 56 www.polymedix.com 56 Guanilib 56 NEBIDO R 56 prodrugs 56 targeting CD# 56 Metastatic Melanoma 56 drug conjugate 56 novel anticancer 56 TOCOSOL Paclitaxel 56 ganetespib 56 selective estrogen receptor 56 Gastrointestinal Cancers Symposium 56 investigational oral 56 J Am Soc 56 Antisense 56 novel RNAi therapeutics 56 CONTAINS FORWARD LOOKING STATEMENTS 56 Recombinant Human 56 BiTE antibody 56 Alzhemed TM 55 anticancer compound 55 www.combinatorx.com 55 Phenoptin 55 inhaled formulation 55 www.oncolyticsbiotech.com 55 Molecular Targets 55 BAY #-# 55 www.allos.com 55 Tarvacin TM 55 phase IIb clinical 55 Denufosol 55 Completes Enrollment 55 optical biosensors 55 nonclinical studies 55 RGB # 55 SARMs 55 siRNA therapeutics